A new series of sixteen multifunctional N-benzyl-piperidine-aryl-acylhydrazones hybrid derivatives was synthesized and evaluated for multi-target activities related to Alzheimer's disease (AD). The molecular hybridization approach was based on the combination, in a single molecule, of the pharmacophoric N-benzyl-piperidine subunit of donepezil, the substituted hydroxy-piperidine fragment of the AChE inhibitor LASSBio-767, and an acylhydrazone linker, a privileged structure present in a number of synthetic aryl- and aryl-acylhydrazone derivatives with significant AChE and anti-inflammatory activities. Among them, compounds 4c, 4d, 4g and 4j presented the best AChE inhibitory activities, but only compounds 4c and 4g exhibited concurrent anti-inflammatory activity in vitro and in vivo, against amyloid beta oligomer (AβO) induced neuroinflammation. Compound 4c also showed the best in vitro and in vivo neuroprotective effects against AβO-induced neurodegeneration. In addition, compound 4c showed a similar binding mode to donepezil in both acetylated and free forms of AChE enzyme in molecular docking studies and did not show relevant toxic effects on in vitro and in vivo assays, with good predicted ADME parameters in silico. Overall, all these results highlighted compound 4c as a promising and innovative multi-target drug prototype candidate for AD treatment.

Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates

Pruccoli, Letizia;Tarozzi, Andrea;
2018

Abstract

A new series of sixteen multifunctional N-benzyl-piperidine-aryl-acylhydrazones hybrid derivatives was synthesized and evaluated for multi-target activities related to Alzheimer's disease (AD). The molecular hybridization approach was based on the combination, in a single molecule, of the pharmacophoric N-benzyl-piperidine subunit of donepezil, the substituted hydroxy-piperidine fragment of the AChE inhibitor LASSBio-767, and an acylhydrazone linker, a privileged structure present in a number of synthetic aryl- and aryl-acylhydrazone derivatives with significant AChE and anti-inflammatory activities. Among them, compounds 4c, 4d, 4g and 4j presented the best AChE inhibitory activities, but only compounds 4c and 4g exhibited concurrent anti-inflammatory activity in vitro and in vivo, against amyloid beta oligomer (AβO) induced neuroinflammation. Compound 4c also showed the best in vitro and in vivo neuroprotective effects against AβO-induced neurodegeneration. In addition, compound 4c showed a similar binding mode to donepezil in both acetylated and free forms of AChE enzyme in molecular docking studies and did not show relevant toxic effects on in vitro and in vivo assays, with good predicted ADME parameters in silico. Overall, all these results highlighted compound 4c as a promising and innovative multi-target drug prototype candidate for AD treatment.
Dias Viegas, Flávia Pereira; de Freitas Silva, Matheus; Divino da Rocha, Miguel; Castelli, Maísa Rosa; Riquiel, Mariana Máximo; Machado, Rafael Pereira; Vaz, Sarah Macedo; Simões de Lima, Laís Medeiros; Mancini, Karla Cristine; Marques de Oliveira, Patrícia Cruz; Morais, Élida Parreira; Gontijo, Vanessa Silva; da Silva, Fernanda Motta R.; D'Alincourt da Fonseca Peçanha, Dora; Castro, Newton Gonçalves; Neves, Gilda A.; Giusti-Paiva, Alexandre; Vilela, Fabiana Cardoso; Orlandi, Lidiane; Camps, Ihosvany; Veloso, Márcia Paranho; Leomil Coelho, Luis Felipe; Ionta, Marisa; Ferreira-Silva, Guilherme Álvaro; Pereira, Rodrigo Machado; Dardenne, Laurent E.; Guedes, Isabella Alvim; de Oliveira Carneiro Junior, Wellerson; Quaglio Bellozi, Paula Maria; Pinheiro de Oliveira, Antônio Carlos; Ferreira, Fábio Furlan; Pruccoli, Letizia; Tarozzi, Andrea; Viegas, Claudio*
File in questo prodotto:
File Dimensione Formato  
j.ejmech.2018.01.066.pdf

embargo fino al 31/01/2020

Tipo: Postprint
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 3.08 MB
Formato Adobe PDF
3.08 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/627678
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact